Depressive disorder
Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study
Neurocrine Biosciences; Takeda; NBI-1070770; Phase 2 failure; major depressive disorder; depression drug; psychiatry pipeline; clinical trial results; drug licensing; pharmaceutical setbacks
Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal
Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder
Relmada Therapeutics Considers Strategic Alternatives Following Depression Drug Setbacks
Relmada Therapeutics, depression drug, REL-1017, strategic alternatives, sale, major depressive disorder, NMDA receptor blocker
Biogen and Sage Discontinue Plans for Major Depressive Disorder Approval for Zurzuvae
Biogen, Sage Therapeutics, Zurzuvae, postpartum depression, major depressive disorder, FDA approval
Seaport Therapeutics Secures $225M Series B Funding to Revolutionize Neuropsychiatric Medicines
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, clinical-stage pipeline, major depressive disorder, generalized anxiety disorder.
Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar
Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials